Micromet Signs $477M Deal with Sanofi-Aventis
Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.
Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.
Copyright © 2024 | WordPress Theme by MH Themes